Recent Advances in Cancer Therapy

  • ID: 4327584
  • Report
  • 15 pages
  • Frost & Sullivan
1 of 3
This edition of the Genetic Technology TOE depicts trends across cancer therapy. Stem cell therapies, check-point inhibitors, and other novel biomarkers are illustrated through the most recent innovations in immuno-oncology. A summary of industry-funded clinical trials for stem cell therapy in blood cancers is also presented.

The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.
Note: Product cover images may vary from those shown
2 of 3
Innovations in Cancer Therapy
  • Leveraging Umbilical Cord Stem Cells for Treating Blood Cancers
  • Combining Checkpoint Inhibition with Immune Activation for Enhanced Cancer Therapy
  • Novel Immunotherapy that Leverages Anti-inflammatory Functions
  • Leveraging Predictive Biomarkers for Precision Oncology Applications
Clinical Trial Analysis and Industry Interactions
  • Clinical Trial Analysis
  • Industry Interactions
Note: Product cover images may vary from those shown
3 of 3


4 of 3
Note: Product cover images may vary from those shown